HR 5850 · 118th Congress 2023โ€“2025, ended

To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

Latest action · Oct 6, 2023 Referred to the Subcommittee on Health.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedSep 29, 2023
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Cosponsors 1

Members who signed on, in the order they did. All signed on Sep 29, 2023.

SeatCosponsorSigned on
R-MIJohn R. MoolenaarOriginalSep 29, 2023

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Sep 29, 2023
Health Subcommittee
Referred Oct 6, 2023

Actions 3

Everything that happened, newest first.

  1. Oct 6, 2023Referred to the Subcommittee on Health.
  2. Sep 29, 2023Introduced in House
  3. Sep 29, 2023Referred to the House Committee on Energy and Commerce.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: Congress has the power to enact this legislation pursuant to the following--Article 1, Section 8 of the U.S. Constitution. The single subject of this legislation is: To prohibit the use of federal funds for implementing REMS for Mifepristone and to nullify the January 2023 REMS modifications for mifepristone.

The sponsor’s statement, as printed in the Congressional Record, vol. 169, no. 159, September 29, 2023, page H4911.

Titles 1

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Sep 29, 2023Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.